炎症性肠病的抗体特征：当前的发展和未来的应用。

Antibody signatures in inflammatory bowel disease: current developments and future applications.

机构信息

Department of Gastroenterology and Hepatology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.

Diagnostic and Research Institute of Hygiene, Microbiology and Environmental Medicine, Medical University Graz, Graz, Austria.

出版信息

Trends Mol Med. 2022 Aug;28(8):693-705. doi: 10.1016/j.molmed.2022.05.004. Epub 2022 May 31.

DOI:10.1016/j.molmed.2022.05.004

PMID:35654641

Abstract

Adequate functioning of the intestinal barrier is required in order to repel invading pathogens while tolerating commensal microbiota and self-antigens. Inflammatory bowel diseases (IBDs), encompassing Crohn's disease (CD) and ulcerative colitis (UC), are characterized by disrupted intestinal barrier integrity, resulting in excessive passage of luminal antigens and the activation of aberrant immune responses against otherwise unexposed antigens. A comprehensive overview of the exact antigens associated with IBD is still lacking, but recent innovative antibody profiling technologies have enabled systematic characterization of humoral immunity in health and disease. Here, we review established serological antibodies and novel high-throughput methods, such as protein arrays, phage-display immunoprecipitation sequencing (PhIP-Seq), and B cell receptor sequencing (BCRseq), and provide an outlook on their applications in disease diagnostics, therapeutic interventions, and opportunities for prevention in IBD.

摘要

为了抵御入侵病原体，同时耐受共生菌群和自身抗原，肠道屏障需要正常发挥功能。炎症性肠病（IBD）包括克罗恩病（CD）和溃疡性结肠炎（UC），其特征是肠道屏障完整性受损，导致腔抗原过度通过，并对原本未暴露的抗原产生异常免疫反应。尽管目前仍缺乏与 IBD 相关的确切抗原的全面概述，但最近的创新抗体分析技术已经能够对健康和疾病中的体液免疫进行系统表征。在这里，我们回顾了已建立的血清学抗体和新型高通量方法，如蛋白质阵列、噬菌体展示免疫沉淀测序（PhIP-Seq）和 B 细胞受体测序（BCRseq），并展望了它们在 IBD 疾病诊断、治疗干预和预防中的应用。